<DOC>
	<DOCNO>NCT00006233</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy fludarabine use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Sometimes transplanted cell reject body 's normal tissue . Donor lymphocytes treated laboratory may prevent . PURPOSE : Phase II trial study effectiveness chemotherapy , total-body irradiation , peripheral stem cell transplantation , lymphocyte infusion treat patient stage IV melanoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Total-Body Irradiation , Peripheral Stem Cell Transplantation , Lymphocyte Infusion Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient metastatic melanoma treat nonmyeloablative allogeneic peripheral blood stem cell transplantation fludarabine total body irradiation , follow cyclosporine mycophenolate mofetil , follow donor lymphocyte infusion . - Determine disease-free overall survival patient treat regimen . - Determine toxicity nonmyeloablative conditioning regimen patient . OUTLINE : Patients receive condition regimen comprise fludarabine IV day -4 -2 total body irradiation day 0 . Allogeneic peripheral blood stem cell infuse day 0 . Patients receive oral cyclosporine twice day day -3 35 tapered day 56 oral mycophenolate mofetil 3 time day day 0-40 . Patients mixed chimerism graft-versus-host disease day 56 receive donor lymphocyte infusion ( DLI ) 30 minute day 65 unless evidence increase donor chimerism . DLI may repeat every 65 day 4 dos . Patients follow weekly 3 month , monthly 6 month , every 6 month year 2 , annually year 5 . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV melanoma Partial response , minor response , stable disease 2 regimen chemotherapy , immunotherapy , chemoimmunotherapy Bidimensionally measurable disease palpation clinical exam radiographic image HLA genotypically identical sibling donor available Not identical twin Age 12 74 No ocular melanoma No active untreated brain metastasis transmural gastrointestinal metastasis PATIENT CHARACTERISTICS : Age : 18 64 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT less 2 time ULN Renal : Creatinine clearance least 40 mL/min Cardiovascular : LVEF least 40 % history congestive heart failure No uncontrolled hypertension Pulmonary : DLCO least 50 % predict No continuous supplementary oxygen Other : Not pregnant Fertile patient must use effective contraception 1 year study participation HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent growth factor mycophenolate mofetil administration Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>